Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$7.17
+0.25 (+3.61%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $81.0M · quality 79.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
32.6x
↑EV/EBITDA
16.1x
↑ROE
6.8%
↑Gross Margin
29.7%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.4%
FCF CAGR
+18.3%
FCF margin
17.6%
FCF / Net income
1.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $460.4M · net income $65.0M · FCF $81.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $460.4M | $460.4M | $473.5M | $462.8M | $428.3M |
| Net Income | $65.0M | $65.0M | $49.3M | $64.9M | $60.9M |
| EBITDA | $121.7M | $121.7M | $105.0M | $117.6M | $106.0M |
| EPS | 0.22 | 0.22 | 0.16 | 0.22 | 0.20 |
| Gross Margin | 29.7% | 29.7% | 25.5% | 29.4% | 27.3% |
| Operating Margin | 14.3% | 14.3% | 10.4% | 13.1% | 12.1% |
| Net Margin | 14.1% | 14.1% | 10.4% | 14.0% | 14.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Current Ratio | 3.08 | 3.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $81.0M | $81.0M | $49.9M | $93.3M | $48.9M |
| Returns | |||||
| ROE | 6.8% | 6.8% | 5.4% | 7.2% | 7.1% |
| Valuation | |||||
| P/E | 32.59 | 32.59 | 38.25 | 39.95 | 43.90 |
| EV/EBITDA | 16.12 | 16.12 | 14.70 | 20.06 | 22.18 |
| P/B | 2.21 | 2.21 | 2.06 | 2.88 | 3.13 |
| Growth & Yield | |||||
| Revenue Growth | -2.8% | -2.8% | 2.3% | 8.0% | — |
| EPS Growth | 37.5% | 37.5% | -27.3% | 10.0% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
42.5%
EPS terminal req.
$0.64
Spread vs growth
-5.0%
5Y implied EPS CAGR
28.5%
EPS terminal req.
$0.77
Spread vs growth
9.0%
10Y implied EPS CAGR
18.9%
EPS terminal req.
$1.24
Spread vs growth
18.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.8%
Start / end P/E
44.6x → 32.6x
EPS bridge
0.16 → 0.22
Residual
-10.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.